LUGANO, Switzerland – The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component.
- Novel data, new insights, and reinforced potential of the use of Tumour Infiltrating Lymphocytes (TIL) therapy in patients with melanoma
Related content: 119O, 48O, 50MO, 66MO, Educational session on Thursday, 7 December at 8:30 CET
- New therapeutic approaches in nasopharyngeal carcinoma and in relapsed/refractory solid tumours
Related content: 67MO and 118O
- Further evidence of failures of Tyrosine Kinase Inhibitor (TKI) and Immune Checkpoint Inhibitors (CPI) combination in non-small cell lung cancer: Insights for future research directions
Related content: 64O, 65O, Educational session on Wednesday, 6 December at 16:15 CET
Award keynote lecture
- Lymphocytes as a “Living Drug” for the Treatment of Cancer, by Steven A. Rosenberg, 6 December 2023, 13:30-14:05 CET
The results of 220 studies will be presented and published online as a supplement to IOTECH.
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities. To apply for press accreditation, please fill out the form available here. Requests for press accreditation should be sent by Tuesday, 5 December. Please be kindly informed that onsite press accreditation will not be possible.
ESMO Press Office
Notes to editors
Please make sure to use the official name of the meeting in your reports: ESMO Immuno-Oncology Congress 2023 and the official congress hashtag #ESMOImmuno23. Follow it to stay up to date and use it to take part in the conversation on X (Twitter), LinkedIn, Instagram, Facebook